On Apr. 26, 2024, the California Institute for Regenerative Medicine (CIRM) announced it had approved awarding nearly $31 million to fund various clinical research across the spectrum of cancers and eye disease.

The awards will support three projects in the Agency’s clinical program which provides funding for eligible stem cell and gene therapy-based projects through all stages of clinical trial development. These awards bring the number of CIRM-funded clinical trials to 106.

With $5.5 billion in funding and more than 150 active stem cell programs in their portfolio, CIRM is one of the world’s largest institutions dedicated to helping people by bringing the future of cellular medicine closer to reality.